Amarin Corp Plcuk (AMRN) Treasury Shares (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Treasury Shares of $69.0 million for Q1 2026, up 3.92% year-over-year from $66.4 million in Q1 2025, and up 2.5% quarter-over-quarter from $67.4 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Treasury Shares (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Treasury Shares data on file, last reported at $69.0 million in Q1 2026.
- Treasury Shares for Q1 2026 came in at $69.0 million, up 3.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.0 million (up 3.92% YoY), and the FY2025 annual result was $67.4 million, up 3.11% from the prior year.
- Treasury Shares advanced to $69.0 million in Q1 2026 per AMRN's latest filing, from $67.4 million in the prior quarter.
- Over five years, Treasury Shares peaked at $16.0 million in Q1 2026 and troughed at -$13.3 million in Q2 2025.
- A 5-year average of -$5.4 million and a median of -$9.0 million in 2023 frame the typical range for Treasury Shares.
- On a YoY basis, Treasury Shares climbed as much as 5.02% in 2022 and fell as far as 1.72% in 2022.
- A 5-year view of Treasury Shares shows it stood at $61.8 million in 2022, then gained by 3.21% to $63.8 million in 2023, then grew by 2.47% to $65.3 million in 2024, then climbed by 3.11% to $67.4 million in 2025, then rose by 2.5% to $69.0 million in 2026.
- Business Quant data shows AMRN's Treasury Shares at $69.0 million in Q1 2026, $67.4 million in Q4 2025, and $67.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 76.26 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 77.08 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 1.11 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | - |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 3.94 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 881.00 Mn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn | 15.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.95 Mn |
| Mar 31, 2026 | 15.95 Mn |
| Mar 31, 2026 | 69.05 Mn |
| Mar 31, 2026 | 69.05 Mn |
| Dec 31, 2025 | 67.36 Mn |
| Dec 31, 2025 | 13.63 Mn |
| Dec 31, 2025 | 67.36 Mn |
| Dec 31, 2025 | 13.63 Mn |
| Sep 30, 2025 | 13.63 Mn |
| Sep 30, 2025 | 67.36 Mn |
| Sep 30, 2025 | 67.36 Mn |
| Sep 30, 2025 | 13.63 Mn |
| Jun 30, 2025 | 67.11 Mn |
| Jun 30, 2025 | -13.31 Mn |
| Jun 30, 2025 | -13.31 Mn |
| Jun 30, 2025 | 67.11 Mn |
| Mar 31, 2025 | -12.48 Mn |
| Mar 31, 2025 | 66.45 Mn |
| Mar 31, 2025 | 66.45 Mn |
| Mar 31, 2025 | -12.48 Mn |